Radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma: dosimetric comparison and risk assessment of solid secondary cancer |
Bae, Sun Hyun
(Department of Radiation Oncology, Soonchunhyang University Bucheon Hospital)
Kim, Dong Wook (Department of Radiation Oncology, Kyung Hee University Hospital at Gangdong) Kim, Mi-Sook (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) Shin, Myung-Hee (Department of Social and Preventive Medicine, Sungkyunkwan University School of Medicine) Park, Hee Chul (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) Lim, Do Hoon (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) |
1 | Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92. |
2 | Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49. DOI |
3 | Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003;21:4157-64. DOI |
4 | Koch P, Probst A, Berdel WE, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 2005;23:7050-9. DOI |
5 | Lin ML, Wirth A, Chao M, et al. Radiotherapy for low-grade gastric marginal zone lymphoma: a retrospective study. Intern Med J 2007;37:172-80. DOI |
6 | Vrieling C, de Jong D, Boot H, de Boer JP, Wegman F, Aleman BM. Long-term results of stomach-conserving therapy in gastric MALT lymphoma. Radiother Oncol 2008;87:405-11. DOI |
7 | Gobbi PG, Corbella F, Valentino F, et al. Complete long-term response to radiotherapy of gastric early-stage marginal zone lymphoma resistant to both anti-Helicobacter pylori antibiotics and chemotherapy. Ann Oncol 2009;20:465-8. |
8 | Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer 2010;116:3815-24. DOI |
9 | Okada H, Takemoto M, Kawahara Y, et al. A prospective analysis of efficacy and long-term outcome of radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma. Digestion 2012;86:179-86. DOI |
10 | Wirth A, Gospodarowicz M, Aleman BM, et al. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Ann Oncol 2013;24:1344-51. DOI |
11 | Abe S, Oda I, Inaba K, et al. A retrospective study of 5-year outcomes of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy. Jpn J Clin Oncol 2013;43:917-22. DOI |
12 | Kim SW, Lim DH, Ahn YC, et al. Clinical outcomes of radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 2013;19:6062-8. DOI |
13 | Della Biancia C, Hunt M, Furhang E, Wu E, Yahalom J. Radiation treatment planning techniques for lymphoma of the stomach. Int J Radiat Oncol Biol Phys 2005;62:745-51. DOI |
14 | Ruben JD, Lancaster CM, Jones P, Smith RL. A comparison of out-of-field dose and its constituent components for intensity-modulated radiation therapy versus conformal radiation therapy: implications for carcinogenesis. Int J Radiat Oncol Biol Phys 2011;81:1458-64. DOI |
15 | Kataria T, Sharma K, Subramani V, Karrthick KP, Bisht SS. Homogeneity index: an objective tool for assessment of conformal radiation treatments. J Med Phys 2012;37:207-13. DOI |
16 | Feuvret L, Noel G, Mazeron JJ, Bey P. Conformity index: a review. Int J Radiat Oncol Biol Phys 2006;64:333-42. DOI |
17 | Schneider U, Zwahlen D, Ross D, Kaser-Hotz B. Estimation of radiation-induced cancer from three-dimensional dose distributions: concept of organ equivalent dose. Int J Radiat Oncol Biol Phys 2005;61:1510-5. DOI |
18 | Schneider U, Kaser-Hotz B. Radiation risk estimates after radiotherapy: application of the organ equivalent dose concept to plateau dose-response relationships. Radiat Environ Biophys 2005;44:235-9. DOI |
19 | National Academy of Sciences. Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2. Washington, DC: The National Academies Press; 2006. |
20 | Statistics Korea. Complete life-table 2012 [Internet]. Daejeon: Statistics Korea; c2016 [cited 2016 Nov 20]. Available from: http://kostat.go.kr. |
21 | Luxton RW. Radiation nephritis: a long-term study of 54 patients. Lancet 1961;2:1221-4. |
22 | Tanaka H, Hayashi S, Ohtakara K, Hoshi H. Hepatic dysfunction after radiotherapy for primary gastric lymphoma. J Radiat Res 2013;54:92-7. DOI |
23 | Lee IJ, Seong J, Koom WS, et al. Selection of the optimal radiotherapy technique for locally advanced hepatocellular carcinoma. Jpn J Clin Oncol 2011;41:882-9. DOI |
24 | Chen D, Wang R, Meng X, et al. A comparison of liver protection among 3-D conformal radiotherapy, intensitymodulated radiotherapy and RapidArc for hepatocellular carcinoma. Radiat Oncol 2014;9:48. DOI |
25 | Berrington de Gonzalez A, Curtis RE, Kry SF, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 2011;12:353-60. DOI |
26 | Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006;65:1-7. DOI |